C alcific aortic valve disease is the most common indication for surgical valve replacement in the world. 1 For years this disease was thought to be a passive degenerative phenomenon. Understanding of the cellular mechanisms of this valve lesion will present new cellular therapeutic options to slow disease progression. In this study by Egan et al, 2 they identify for the first time in human calcifying aortic valves a population of circulating osteogenic precursor cells (COP) in calcified human aortic valves. Their finding of these CD45 ϩ OCN ϩ COP cells in areas of calcification and not in the unaffected calcified tissues provides another level of evidence that mesenchymal derived cell populations are responsible for the development of osteogensis in the calcified aortic valve. Specifically, the study demonstrated that these cells were localized to areas of confirmed endochondral ossification and bone formation. Within the regions of interest there were areas of mature bone with the characteristic architecture including osteocytes and bone lining cells. However, within the limits of the study there was no consistent involvement of the valve leaflet layers as the areas of endochondral ossification were found to extend to variable depths. The conclusions from this study provides the first evidence in human calcifying aortic valve tissue that a novel cellular origin is found on the calcific aortic valve and that these COP cells play a role in the cellular mechanisms of osteogensis.
See accompanying article on page 2965
Previously, we and Mohler et al have demonstrated that aortic valve calcification is associated with endochondral bone formation and an osteoblast bone-like phenotype. 3, 4 This bone phenotype is regulated by canonical Wnt pathway in experimental cardiovascular calcification. 5, 6 We have also shown that the canonical Wnt/Lrp5 pathway is upregulated in diseased human valves from patients with valvular heart disease. 7 Bone and cartilage are major tissues in the vertebrate skeletal system, which is primarily composed of 3 cell types: osteoblasts, chrondrocytes, and osteoclasts. In the developing embryo, osteoblast and chrondrocytes both differentiate from common mesenchymal progenitors in situ, whereas osteoclasts are of hematopoietic origin and brought in later by invading blood vessels. Osteoblast differentiation and maturation lead to bone formation controlled by 2 distinct mechanisms: intramembranous and endochondral ossification, both starting from mesenchymal condensations.
Two osteoblast-specific transcripts have been identified: (1) Cbfa1 and (2) osteocalcin. The transcription factor Cbfa1 8 has all the attributes of a "master gene " differentiation factor for the osteoblast lineage and bone matrix gene expression. During embryonic development, Cbfa1 expression precedes osteoblast differentiation and is restricted to mesenchymal cells destined to become osteoblast. In addition to its critical role in osteoblast commitment and differentiation, Cbfa1 appears to control osteoblast activity, ie, the rate of bone formation by differentiated osteoblasts The regulatory mechanism of osteoblast differentiation from osteoblast progenitor cells as shown in Figure A into terminally differentiated cells is via a well-orchestrated and well-studied pathway that involves initial cellular proliferation events and then synthesis of bone matrix proteins, which requires the actions of specific paracrine/hormonal factors/BMP and the activation of the canonical Wnt pathway. 9 In a previous study by Suda et al, they have shown that these isolated COP cells can express BMP and can form bone in vivo. 10 Confirming the hypothesis that these COP cells are capable of homing to sites of valve calcification and neovascularization and form bone. The studies to date indicate that the cellular origins of bone forming cells in the calcifying aortic valve have 2 distinct pathways as shown in Figure B . The cells can either be the COP cell capable of differentiating to bone at the site of calcification and disease, or the interstitial aortic valve cell that is capable of differentiating to bone in vivo, as described in the most recent National Heart and Lung and Blood Institute Working Group paper on calcific aortic valve disease. 11 Further evidence for the circulating stem cell was published in a study by Tanaka et al, which demonstrated using transplanted bone marrow cells composed of 17% of the population of calcifying cells in the native atherosclerotic valve. 12 The presence of variable depths of the COP cell in the calcific valve is consistent with the hypothesis that these cells can home to the diseased valve but are not responsible for the entire bone formation process. The native interstitial cells also have the potential to differentiate to bone in situ and contribute to the calcifying cells in the native valve. The contribution of these 2 cell types toward the development of calcification in the aortic valve requires further ongoing investigation. In summary, this study provides incremental understanding into the role of calcific aortic valve disease. In the future, these studies will provide the roadmap for targeted cellular therapies for the treatment of this disease process to 
